Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Ariad Falls as Late-Stage Iclusig Study is Stopped

By Pharmaceutical Processing | October 18, 2013

Shares of Ariad Pharmaceuticals tumbled again Friday after the company said it is ending a study of its cancer drug Iclusig because of recently disclosed side effects.

Ariad said it is stopping a late-stage trial of Iclusig as a treatment for newly diagnosed chronic myeloid leukemia because of “arterial thrombotic events,” or side effects related to blood clots in patients’ arteries. The company said last week that those blockages were occurring more often than it had previously believed. Ariad said it is stopping the trial by mutual agreement with the Food and Drug Administration, and patients are being removed from treatment and will be transferred to care of their physicians.

The company’s shares dropped $1.79, or 40 percent, to $2.71 in morning trading. Earlier in the session shares touched $2.62, their lowest point since February 2009.

The Food and Drug Administration approved Iclusig in December to treat two rare types of leukemia: treatment-resistant chronic myeloid leukemia and acute lymphoblastic leukemia in patients with a type of chromosome abnormality. It is the Cambridge, Mass., company’s first approved product, and Iclusig sales totaled $13.9 million in the second quarter. The company is running additional studies to expand the marketing approval and improve sales.

On Oct. 9 the company disclosed a higher rate of side effects related to blood clots. Ariad Pharmaceuticals Inc. said that after two years of research in another late-stage study, 11.8 percent of patients treated with the drug suffered a serious blood clot in an artery, worsening from the 8 percent rate after 11 months. The FDA halted enrollment of patients in new studies, although treatment of patients who were already enrolled in those studies hadn’t stopped. The company said patients would have reduced dosages of Iclusig, however.

Iclusig is a pill intended to be taken once per day. In the latest trial, which was called EPIC, a total of 307 patients were being treated with either Iclusig or Novartis AG’s drug Gleevec.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE